Temozolomide

Name: Temozolomide
Brand: Selleck Chemicals
SKU: S1237
Rating: 5 (103 reviews)

For research use only.

Catalog No.S1237 Synonyms: CCRG81045, NSC 362856,TMZ

103 publications

CAS No. 85622-93-1

Temozolomide (CCRG81045, NSC 362856, TMZ) is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells. Temozolomide induces apoptosis and exhibits antitumor activity.

Selleck's Temozolomide has been cited by 103 publications

Nature, 2020, 580(7804):517-523.

PubMed: 32322066 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Theranostics, 2021, 11(4):1991-2005

PubMed: 33408794 ( click the link to review the publication )

Hum Mol Genet, 2021, ddab009

PubMed: 33438023 ( click the link to review the publication )

Exp Ther Med, 2021, 21(2):175

PubMed: 33456542 ( click the link to review the publication )

Autophagy, 2021, 1-15

PubMed: 33629929 ( click the link to review the publication )

Oncol Rep, 2021, 45(4)34

PubMed: 33649855 ( click the link to review the publication )

J Clin Invest, 2020, 134132

PubMed: 33016930 ( click the link to review the publication )

Nat Commun, 2020, 11(1):550

PubMed: 31992716 ( click the link to review the publication )

J Clin Invest, 2020, 139542

PubMed: 33332283 ( click the link to review the publication )

J Thorac Oncol, 2020, 10.1016/j.jtho.2020.01.012

PubMed: 32004714 ( click the link to review the publication )

Clin Cancer Res, 2020, clincanres.2585.2020

PubMed: 33229458 ( click the link to review the publication )

Oncogene, 2020, 5

PubMed: 32372061 ( click the link to review the publication )

EBioMedicine, 2020, 59:102971

PubMed: 32846370 ( click the link to review the publication )

Cell Death Dis, 2020, 11(10):890

PubMed: 33087705 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 22;5(1):44

PubMed: 32317623 ( click the link to review the publication )

Cell Chem Biol, 2020, S2451-9456(20)30384-6

PubMed: 33113406 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(10):2001-2011

PubMed: 32737157 ( click the link to review the publication )

Aging (Albany NY), 2020, 29;12(2):1685-1703

PubMed: 32003751 ( click the link to review the publication )

Neuroendocrinology, 2020, 3

PubMed: 32241015 ( click the link to review the publication )

Mater Sci Eng C Mater Biol Appl, 2020, 108:110191

PubMed: 31923988 ( click the link to review the publication )

J Cell Mol Med, 2020, 10.1111/jcmm.15114

PubMed: 32150671 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(21)E8353

PubMed: 33171763 ( click the link to review the publication )

Sci Rep, 2020, 10(1):3836

PubMed: 32123273 ( click the link to review the publication )
Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Front Neurosci, 2020, 14:598266

PubMed: 33328869 ( click the link to review the publication )

Fluids Barriers CNS, 2020, 2;17(1):37

PubMed: 32487241 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2020, 146(7):1659-1670

PubMed: 32279088 ( click the link to review the publication )

Transl Oncol, 2020, 13(1):70-78

PubMed: 31810002 ( click the link to review the publication )

PLoS One, 2020, 22;15(4):e0231470

PubMed: 32320427 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Cancer Res, 2020, canres.132.2020

PubMed: 32680921 ( click the link to review the publication )

Cell Signal, 2020, 71:109598

PubMed: 32165236 ( click the link to review the publication )

J Exp Clin Cancer Res, 2020, 39(1):137

PubMed: 32677981 ( click the link to review the publication )

Cancer Cell Int, 2020, 20:71

PubMed: 32165861 ( click the link to review the publication )

Theranostics, 2020, 10(7):3351-3365

PubMed: 32194873 ( click the link to review the publication )

Cancer Cell Int, 2020, 20:65

PubMed: 32158355 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4529

PubMed: 31586101 ( click the link to review the publication )

J Pineal Res, 2019, 66(3):e12556

PubMed: 30648757 ( click the link to review the publication )

Autophagy, 2019, 15(6):1100-1111

PubMed: 30654687 ( click the link to review the publication )

Cancers (Basel), 2019, 11(12)

PubMed: 31810230 ( click the link to review the publication )

Cell Death Dis, 2019, 10(12):881

PubMed: 31754113 ( click the link to review the publication )

FASEB J, 2019, 33(12):13476-13491

PubMed: 31570001 ( click the link to review the publication )

Hum Mol Genet, 2019, 28(16):2738-2751

PubMed: 31087038 ( click the link to review the publication )

Hum Mol Genet, 2019, 10.1093/hmg/ddz152

PubMed: 31518391 ( click the link to review the publication )

Eur J Pharm Biopharm, 2019, 136:156-163

PubMed: 30682492 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(3):606-617

PubMed: 31565489 ( click the link to review the publication )
Endocrinology, 2019, 160(11):2600-2617

PubMed: 31322702 ( click the link to review the publication )

Cancer Commun (Lond), 2019, 39(1):81

PubMed: 31796105 ( click the link to review the publication )

Eur J Pharmacol, 2019, 852:42-50

PubMed: 30851271 ( click the link to review the publication )

J Oncol, 2019, 2019:1805841

PubMed: 31275377 ( click the link to review the publication )

Oncol Lett, 2019, 18(3):2509-2517

PubMed: 31402948 ( click the link to review the publication )

Anticancer Res, 2019, 39(12):6731-6741

PubMed: 31810938 ( click the link to review the publication )

Mol Imaging, 2019, 18:1536012119870899

PubMed: 31478435 ( click the link to review the publication )

Pharmaceutics, 2019, 11(8)E401

PubMed: 31405159 ( click the link to review the publication )

Nat Cell Biol, 2018, 20(10):1203-1214

PubMed: 30202050 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):446-462

PubMed: 29202477 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2494

PubMed: 29950602 ( click the link to review the publication )

Genome Res, 2018, 28(8):1207-1216

PubMed: 29898900 ( click the link to review the publication )

Cancer Res, 2018, 78(23):6632-6642

PubMed: 30322863 ( click the link to review the publication )

J Control Release, 2018, 269:245-257

PubMed: 29162480 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):32

PubMed: 29486795 ( click the link to review the publication )

Cancer Lett, 2018, 433:210-220

PubMed: 30008386 ( click the link to review the publication )

Mol Pharm, 2018, 15(2):609-618

PubMed: 29308904 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(5):777-790

PubMed: 29431617 ( click the link to review the publication )

Sci Rep, 2018, 8(1):7222

PubMed: 29740146 ( click the link to review the publication )

Int J Oncol, 2018, 52(1):295-304

PubMed: 29115581 ( click the link to review the publication )

Cell Cycle, 2018, 17(10):1199-1211

PubMed: 29886801 ( click the link to review the publication )

Cancer Med, 2018, 7(4):1404-1415

PubMed: 29479863 ( click the link to review the publication )

J Pharm Sci, 2018, 107(3):922-933

PubMed: 29162424 ( click the link to review the publication )

Onco Targets Ther, 2018, 11:7031-7040

PubMed: 30410360 ( click the link to review the publication )
Oncol Lett, 2018, 16(5):5607-5614

PubMed: 30344715 ( click the link to review the publication )

Medicines (Basel), 2018, 5(2)

PubMed: 29925764 ( click the link to review the publication )

J Neurooncol, 2018,

PubMed: 29564747 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(2):523-535

PubMed: 27440269 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(20):6239-6253

PubMed: 28698200 ( click the link to review the publication )

Neuro Oncol, 2017, 20(2):236-248

PubMed: 29016925 ( click the link to review the publication )

Cell Syst, 2017, 4(6-:600-610

PubMed: 28601558 ( click the link to review the publication )

Cancer Lett, 2017, 386:131-140

PubMed: 27894958 ( click the link to review the publication )

Cell Death Dis, 2017, 8(10):e3062

PubMed: 28981092 ( click the link to review the publication )

Mol Oncol, 2017, 11(2):180-193

PubMed: 28098415 ( click the link to review the publication )

Hum Mol Genet, 2017, 26(22):4375-4387

PubMed: 28973155 ( click the link to review the publication )

Eur J Med Chem, 2017, 127:691-702

PubMed: 27823879 ( click the link to review the publication )

Oncotarget, 2017, 8(12):18626-18639

PubMed: 28148893 ( click the link to review the publication )

Oncotarget, 2017, 8(18):29865-29886

PubMed: 28415741 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):233-246

PubMed: 27989769 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2017, 1861(9):2282-2292

PubMed: 28687190 ( click the link to review the publication )

JCI Insight, 2017, 2(24)

PubMed: 29263302 ( click the link to review the publication )

J Clin Invest, 2016, 126(5):1801-14

PubMed: 27043280 ( click the link to review the publication )

Cancer Res, 2016, 76(1):139-49

PubMed: 26542214 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(10):2302-2313

PubMed: 27474148 ( click the link to review the publication )

Eur J Pharm Biopharm, 2016, 104:7-18

PubMed: 27106606 ( click the link to review the publication )

Neurochem Res, 2016, 41(12):3192-3205

PubMed: 27632183 ( click the link to review the publication )

Oncotarget, 2016, 7(27):41251-41264

PubMed: 27183910 ( click the link to review the publication )

Oncotarget, 2016, 7(43):69961-69975

PubMed: 27564106 ( click the link to review the publication )
Oncotarget, 2016, 7(48):79869-79884

PubMed: 27829215 ( click the link to review the publication )

Tumour Biol, 2016, 37(8):11443-56

PubMed: 27006309 ( click the link to review the publication )

Radiother Oncol, 2015, 116(3):467-72

PubMed: 26163089 ( click the link to review the publication )

PLoS One, 2015, 10(11):e0142704

PubMed: 26571493 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(6):1555-65

PubMed: 24501391 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(12):1646-57

PubMed: 25482938 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(7):1740-7

PubMed: 23406775 ( click the link to review the publication )

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description

Features

Methazolastone is a second-generation alkylating agent.

Targets

DNA replication ^[1]
(L-1210, L-1210/BCNU cells)

In vitro

Methazolastone causes formation of DNA alkali-labile sites which are present in similar amounts and repaired at a similar rate in L-1210 and L-1210/BCNU cell lines. In L-1210 but not in L-1210/BCNU methazolastone induces an arrest of cells in SL-G2-M phases.^[1] Methazolastone sensitivity of both chemo-sensitive and resistant cells (D54-R and U87-R) is enhanced significantly under hyperoxia. Both Methazolastone and hyperoxia are associated with increased phosphorylation of ERK p44/42 MAPK (Erk1/2), but to a lesser extent in D54-R cells, suggesting that Erk1/2 activity may be involved in regulation of hyperoxia and Methazolastone-mediated cell death. Hyperoxia enhances Methazolastone toxicity in GBM cells by induction of apoptosis, possibly via MAPK-related pathways. ^[2] Methazolastone induces in monocytes the DNA damage response pathways ATM-Chk2 and ATR-Chk1 resulting in p53 activation. ^[3] Chronic Methazolastone exposure results in acquired Methazolastone-resistance and elevates miR-21 expression. ^[4] Methazolastone treatment triggers endoplasmic reticula (ER) stress with increased expression of GADD153 and GRP78 proteins, and deceases pro-caspase 12 protein. Methazolastone induces autophagy through mitochondrial damage- and ER stress-dependent mechanisms to protect glioma cells. ^[5]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Kelly	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWPJdVBpPDhiaB?=		NVLpRnZRUUN3ME2xN\|kvOjEkgJpCtgKBkTVwOUWg{txO	M3fMSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OU[wNlgzLz5{NUm2NFI5OjxxYU6=
KellyCis83	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NV:yNVRPPDhiaB?=		Mn7kTWM2OD1{NUGuNFDjiIoEsfMAjVE2Njd3IN88US=>	MmjKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NkCyPFIoRjJ3OU[wNlgzRC:jPh?=
SK-N-AS	NUfSV4tnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MlvpOFghcA>?		NV21d2g{UUN3ME2yNlcvPzEkgJpCtgKBkTJ{LkG1JO69VQ>?	M2ToUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OU[wNlgzLz5{NUm2NFI5OjxxYU6=
SK-N-ASCis24	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVq0PEBp		M{jrWGlEPTB;NEiwMlYx6oDLwsJihKkyODFwMUWg{txO	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl4MEK4Nkc,OjV7NkCyPFI9N2F-
CHP-212	MoLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFfpeZA1QCCq		MW\JR\|UxRTdwOUhihKnDueLCiUCuOlkh\|ryP	M123Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OU[wNlgzLz5{NUm2NFI5OjxxYU6=
CHP-212Cis100	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1zSW\|Q5KGh?		NEPNWGdKSzVyPUmuOVXjiIoEsfMAjVAvQDhizszN	NWrsZoJGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OlAzQDJpPkK1PVYxOjh{PD;hQi=>
U87	MWXGeY5kfGmxbjDBd5NigQ>?	M4PKSFExOCEQvF2=	MWKyOE04OiCq		NHTBOI9qdmS3Y3XzJGRkWjFiZYjwdoV{e2mxbh?=	Ml\3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MEi4OlgoRjJ3OEC4PFY5RC:jPh?=
LN229	NGnsWW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU[wMVUxKM7:TR?=			NVHjbZgxUUN3ME2xOkDPxE1?	NUXRNJlDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OVAzPzNpPkK1O\|UxOjd\|PD;hQi=>
TR-LN229	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NETTSXgxNTVyIN88US=>			MYLJR\|UxRTd5IN88US=>	MoK5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NUCyO\|MoRjJ3N{WwNlc{RC:jPh?=
U87	M2D3NGFxd3C2b4Ppd{BCe3OjeR?=	M13lRVDjiJN{MEFihKnDvU1?	M{\6bFI1KGh?		MUXlcohidmOnczDDVUBqdmS3Y3XkJIFxd3C2b4Ppdy=>	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ6MU[2PEc,OjV4OEG2Olg9N2F-
U251MG	NFvTNnFCeG:ydH;zbZMhSXO\|YYm=	NFjFSYoyODEEoN88US=>	M4X1bVQ5KGh?	MmCyVGJU	NYLNRYRZcW6mdXPld{BieG:ydH;zbZM>	MnniQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4OEC0OlQoRjJ3NkiwOFY1RC:jPh?=
U87MG	M{LC[GFxd3C2b4Ppd{BCe3OjeR?=	NIjZU4YyODEEoN88US=>	NGHhSpI1QCCq	NXz5O5NJWEKV	NGLRcGhqdmS3Y3XzJIFxd3C2b4Ppdy=>	NGDkfnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[4NFQ3PCd-MkW2PFA1PjR:L3G+
U87	NILKd2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIO2VXY2OC1\|NUCg{txO	NFrXPY41QMLiaNMg		MkLrbY5pcWKrdIOgZ4VtdCCpcn;3eIghe2yrZ3j0cJk>	NGTDUZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW1OFIzOyd-MkW1OVQzOjN:L3G+
U118	MorKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoXBOVAuOzVyIN88US=>	NEDrW2Y1QMLiaNMg		NIfVclJqdmirYnn0d{Bk\WyuIHfyc5d1cCC\|bHnnbJRtgQ>?	M2\JSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUW0NlI{Lz5{NUW1OFIzOzxxYU6=
U87	M2\ufGZ2dmO2aX;uJGF{e2G7	NFvZO3IzPTBxM{WwJO69VQ>?	M3HMZ\|Q5yqCqwrC=		NHLte5JmdmijbnPld{BVVVhvaX7keYNm\CCyLWDLR{1x[W5iZHXjdoVie2V?	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV3NEKyN{c,OjV3NUSyNlM9N2F-
U118	MYjGeY5kfGmxbjDBd5NigQ>?	NILNVYszPTBxM{WwJO69VQ>?	M{fzc\|Q5yqCqwrC=		M2O2VYVvcGGwY3XzJHROYC2rbnT1Z4VlKHBvUFvDMZBidiCmZXPy[YF{\Q>?	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV3NEKyN{c,OjV3NUSyNlM9N2F-
U87	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M17mSVI2OC9\|NUCg{txO	M13GbVQ5yqCqwrC=		NV;KPXhKcW6lcnXhd4V{KHSqZTDw[ZJk\W62YXflJI9nKGOnbHzzJIlvKFNiYX7kJGczN04EoHPveJJm[XSnZDD3bZRpKFSPWB?=	NWrwVZVURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1OVQzOjNpPkK1OVU1OjJ\|PD;hQi=>
A375	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVi2NY9kPDkEoHlCpC=>		NVnsdmhJUUN3ME2yOlUh\|ryP	NEDLNpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUWyOFU2Oid-MkW1NlQ2PTJ:L3G+
A2058	NVnHb5AyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3LYeFQ5yqCqwrC=		MWnJR\|UxRTF{IN88US=>	MljPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3MkS1OVIoRjJ3NUK0OVUzRC:jPh?=
M238	NWnHb5dET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M134ZVQ5yqCqwrC=		NYe4VIdNUUN3ME20NEDPxE1?	NHfCSoo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUWyOFU2Oid-MkW1NlQ2PTJ:L3G+
M249	NISyOpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXi0POKhcMLi		M4PndWlEPTB;MkW0JO69VQ>?	Mlu5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3MkS1OVIoRjJ3NUK0OVUzRC:jPh?=
M21	M4TLWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NF74V5c1QMLiaNMg		NV3PcmZoUUN3ME2yNlEh\|ryP	MmPyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3MkS1OVIoRjJ3NUK0OVUzRC:jPh?=
U251	MnfoR5l1d3SxeHn0fUBCe3OjeR?=	MX2yNEDPxE4EoB?=	MlXCOFjDqGkEoB?=		MXTy[YR2[2WmczD0bIUheGW{Y3XueIFo\XNib3[gZ49td26rZYOg[o9zdWWm	NIjGcYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSzOFM5OSd-MkW0N\|Q{QDF:L3G+
LN229	MmTTR5l1d3SxeHn0fUBCe3OjeR?=	MX2yNEDPxE4EoB?=	NYTvd25vPDkEoHlCpC=>		MYPy[YR2[2WmczD0bIUheGW{Y3XueIFo\XNib3[gZ49td26rZYOg[o9zdWWm	NFXCNHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSzOFM5OSd-MkW0N\|Q{QDF:L3G+
U373MG-LUC	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWW3NkBp		M3LvUmlEPTB-NkCwJO69VQ>?	NXuyNmNbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0N\|E6PTNpPkK1OFMyQTV\|PD;hQi=>
U87	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NILNZpozPS1{MECg{txO	MmDUOFjDqGkEoB?=		NWqyfnJ7cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRyMEe0OUc,OjV2MEC3OFU9N2F-
U251	M1HRc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnnTNlUuOjByIN88US=>	MWC0POKhcMLi		MlG0bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NInxS5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSwNFc1PSd-MkW0NFA4PDV:L3G+
U251	NFzKUppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PBb\|ExOC12MECg{txO	NHzHWJE4Oi97NjDo		NELXe2h1cGViYX70bU1xem:uaX\ldoF1cX[nIHXm[oVkfCClYX6gZoUh\W6qYX7j[YQh[nliZ3;zd5lxd2xiZX7oZY5k\WRiwrC=	NXzOSJk1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzO\|UzPzFpPkK1N\|c2OjdzPD;hQi=>
U373	NGH2NVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnfxNVAxNTRyMDFOwG0>	MUi3Nk86PiCq		MUn0bIUh[W62aT3wdo9tcW[ncnH0bZZmKGWoZnXjeEBk[W5iYnWg[Y5p[W6lZXSgZpkh\2:\|c4nwc4wh\W6qYX7j[YQhyqB?	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN5NUK3NUc,OjV\|N{WyO\|E9N2F-
U343	NUfONWlIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoW1NVAxNTRyMDFOwG0>	MlfVO\|IwQTZiaB?=		NGXaOVB1cGViYX70bU1xem:uaX\ldoF1cX[nIHXm[oVkfCClYX6gZoUh\W6qYX7j[YQh[nliZ3;zd5lxd2xiZX7oZY5k\WRiwrC=	NEHFOFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO3OVI4OSd-MkWzO\|UzPzF:L3G+
U87MG-luc2	NWfTcmdYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWi1R3d6OTByLUSwNEDPxE1?	MUC3Nk86PiCq		MoWzeIhmKGGwdHmtdJJwdGmoZYLheIl3\SCnZn\lZ5Qh[2GwIHLlJIVvcGGwY3XkJIJ6KGexc4P5dI9tKGWwaHHuZ4VlKMLi	Ml7uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|N{WyO\|EoRjJ3M{e1NlcyRC:jPh?=
U87	MVrGeY5kfGmxbjDBd5NigQ>?	MmflNlAxKM7:TR?=	M4q5RlQ5KGh?		MlH4bY5kemWjc3XzJGJTS0N\|IH3SUmEh\XiycnXzd4lwdg>?	NXHRdow{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzN\|c4OjFpPkK1N\|M4PzJzPD;hQi=>
U251	MmPUSpVv[3Srb36gRZN{[Xl?	MUOyNFAh\|ryP	MVi0PEBp		NWHkXYl3cW6lcnXhd4V{KEKUQ1OzJI1TVkFiZYjwdoV{e2mxbh?=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN\|N{eyNUc,OjV\|M{e3NlE9N2F-
A172	MYDGeY5kfGmxbjDBd5NigQ>?	NX\IPIdWOjByIN88US=>	M2TZZ\|Q5KGh?		NH7UW5RqdmO{ZXHz[ZMhSlKFQ{OgcXJPSSCneIDy[ZN{cW:w	NHW5OZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOzO\|czOSd-MkWzN\|c4OjF:L3G+
U251	NIPwVZlHfW6ldHnvckBCe3OjeR?=	M{C0dFIxOCEQvF2=	NYfaVoZlPDhiaB?=		MoPkbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGJTS0FzLDDCVmNCOixiUlHEOVEh[W6mIF\BUmNFOg>?	MoHaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|M{e3NlEoRjJ3M{O3O\|IyRC:jPh?=
A172	MUXGeY5kfGmxbjDBd5NigQ>?	NWHzcVNDOjByIN88US=>	MVS0PEBp		NV;0b5U2cW6lcnXhd4V{KHSqZTDlfJBz\XO\|aX;uJI9nKEKUQ1GxMEBDWkODMjygVmFFPTFiYX7kJGZCVkOGMh?=	NW\1Ond{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzN\|c4OjFpPkK1N\|M4PzJzPD;hQi=>
U87	MV7GeY5kfGmxbjDBd5NigQ>?	M1zJb\|IxOCEQvF2=	NV7PcW1OOjRxN{KvNVIxKGh?		M13JXIlv[3KnYYPld{DPu0h{QWig[o9kcSCob4LtZZRqd25idHnt[U1l\XCnbnTlcpRtgQ>?	NYDIPVMxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzN\|c4OjFpPkK1N\|M4PzJzPD;hQi=>
U251	NGrKUW1HfW6ldHnvckBCe3OjeR?=	NE[4SGUzODBizszN	MmqwNlQwPzJxMUKwJIg>		M2HkZYlv[3KnYYPld{DPu0h{QWig[o9kcSCob4LtZZRqd25idHnt[U1l\XCnbnTlcpRtgQ>?	M2X0ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{O3O\|IyLz5{NUOzO\|czOTxxYU6=
A172	NYXSWI5{TnWwY4Tpc44hSXO\|YYm=	M4jp[VIxOCEQvF2=	MUeyOE84Oi9zMkCgbC=>		NW\5cZJwcW6lcnXhd4V{KM7\|SELBXEBnd2OrIH\vdo1ifGmxbjD0bY1mNWSncHXu[IVvfGy7	M{\pe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{O3O\|IyLz5{NUOzO\|czOTxxYU6=
SNB19V	M4WzNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWK3JIQ>	MlLNSG1UVw>?	NXPKUY5{T0l3ME2zOU44yrFzMjFOwG0>	NWnqd4RDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|c1PDFpPkK1Nlc4PDRzPD;hQi=>
SNB19M	Mo\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M132Wlch\A>?	MUXEUXNQ	MnL0S2k2OD12NkmuPeKyQDhizszN	NUPGT4pjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|c1PDFpPkK1Nlc4PDRzPD;hQi=>
SNB19VR	NYf4dGJrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYi3JIQ>	Mk\6SG1UVw>?	MYfHTVUxRTJ6MD6yxtEyQCEQvF2=	NVLJflJQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|c1PDFpPkK1Nlc4PDRzPD;hQi=>
U373V	MoG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHPsZmc4KGR?	NVnafm5OTE2VTx?=	MlfPS2k2OD14OD6wxtE{OiEQvF2=	M4jURlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OFQyLz5{NUK3O\|Q1OTxxYU6=
U373M	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MoHyO{Bl	NGq3T4NFVVOR	MVHHTVUxRTN4OD63xtE5PiEQvF2=	NU\0b\|d7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|c1PDFpPkK1Nlc4PDRzPD;hQi=>
U373VR	NU[0XlRmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2W3UFch\A>?	M3rQb2ROW09?	NIfaRm9IUTVyPUK4PE45yrF\|MzFOwG0>	Mny1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e0OFEoRjJ3Mke3OFQyRC:jPh?=
U87MG	M2C1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3W4O\|ch\A>?	MV7EUXNQ	MYfHTVUxRTN6LkRCtVIxKM7:TR?=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5N{S0NUc,OjV{N{e0OFE9N2F-
HCT116	NY[0Noc1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{GzS\|ch\A>?	NVjmW5l[TE2VTx?=	M4K3bGdKPTB;NUe5MlnDuTN{IN88US=>	M{XQc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OFQyLz5{NUK3O\|Q1OTxxYU6=
DLD1	MlrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXm3JIQ>	M4XuV2ROW09?	NVXDWIhIT0l3ME21NFEvPMLzOUOg{txO	M1fQS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OFQyLz5{NUK3O\|Q1OTxxYU6=
MRC5	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3f2Xlch\A>?	MX\EUXNQ	MorqS2k2OD12NEmuOOKyQCEQvF2=	MnXTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e0OFEoRjJ3Mke3OFQyRC:jPh?=
SNB19V	NXj2TWR6TnWwY4Tpc44hSXO\|YYm=	MonMNVAxKM7:TdMgWG1b	MUSwMVczKGh?		MlXubY5kemWjc3XzJO6{UDKDWDDlfJBz\XO\|aX;uJIJmfHenZX6gNVYh[W6mIEeyJIg>	MnroQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e0OFEoRjJ3Mke3OFQyRC:jPh?=
T98G	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV21M\|ExNzF3IN88US=>	NI\OPI4zPMLiaB?=		NGmxdnVqdmS3Y3XzJINmdGxiZHXheIgh\G:\|ZT3k[ZBmdmSnboTsfUBi\nSncjDjc45kd22rdHHueE11\W2xen;sc41q\GVid3n0bEBPWGV4LWDEWC=>	MoX0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NkK5OlEoRjJ3Mk[yPVYyRC:jPh?=
U251	MkfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXzXdmx[PS9zMD:xOUDPxE1?	MYSyOOKhcA>?		NGjIWGdqdmS3Y3XzJINmdGxiZHXheIgh\G:\|ZT3k[ZBmdmSnboTsfUBi\nSncjDjc45kd22rdHHueE11\W2xen;sc41q\GVid3n0bEBPWGV4LWDEWC=>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4Mkm2NUc,OjV{NkK5OlE9N2F-
T98G	MXnGeY5kfGmxbjDBd5NigQ>?	NE\qfZQyPSEQvF2=	NYCxOnk{OjUEoHi=		MYLpcoNz\WG\|ZYOgSG5CNW[{YXft[Y51[XSrb36gbY4hVlCnNj3QSHQhfHKnYYTl[EBodGmxbXGgZ4VtdHN?	NXjSOGNMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOlI6PjFpPkK1NlYzQTZzPD;hQi=>
U251	MYnGeY5kfGmxbjDBd5NigQ>?	MoLNNVUh\|ryP	Ml;3NlTDqGh?		M4PhS4lv[3KnYYPld{BFVkFvZoLh[41mdnSjdHnvckBqdiCQUHW2MXBFXCC2cnXheIVlKGeuaX;tZUBk\Wyucx?=	MojZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NkK5OlEoRjJ3Mk[yPVYyRC:jPh?=
U-87 MG	NILqUGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4XlNlczKGh?		NF;vWmNKSzVyPUCuPVMhdU4EoB?=	NXjBNWhLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOFU{OzJpPkK1NlQ2OzN{PD;hQi=>
U-118 MG	NUjGdm1TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnjQO\|IhcA>?		M2HvTWlEPTB;MT6wOUBuVcLi	NG\ZOnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK0OVM{Oid-MkWyOFU{OzJ:L3G+
U87	NIC2dnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXSyOEBp		NV7lZ3BWUUN3ME2yOlAvOzRizszNxsA>	M1jsXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUezNlM{Lz5{NUG3N\|I{OzxxYU6=
U87 GSLCs	NVf1Sok4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4\UPVI1KGh?		NXLSWo43UUN3ME23OlYvOTFizszNxsA>	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF5M{KzN{c,OjVzN{OyN\|M9N2F-
U87MG	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NV;hR45UPzJiaB?=		MVrJR\|UxRTF3Lk[yOUDPxE4EoB?=	M3XkNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEWwPVE2Lz5{NUC1NFkyPTxxYU6=
U251	NVHobVNyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUnISGQ1OTByLUSwNEDPxE1?	MmPwOFghcA>?	NEHsWmdFVVOR	Mnv2bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	M4TLS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkKzO\|M3Lz5{NE[yN\|c{PjxxYU6=
U87	NH;WT\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXWNVAxNTRyMDFOwG0>	MUO0PEBp	M1W5VGROW09?	M{DGOYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	Mn\nQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MkO3N\|YoRjJ2NkKzO\|M3RC:jPh?=
MDA-MB-231-br	M1HUXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGrp[pExNTFyIN88US=>	MVi0PEBp	MlTYSG1UVw>?	NYTtWHhtcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NUOzeGQyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2NlM4OzZpPkK0OlI{PzN4PD;hQi=>
HCC-1937	NIPNe4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUPLT4ZkOC1\|MECg{txO	M3\tXVQ5KGh?	Ml;SSG1UVw>?	NXm4UIVEcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MnTBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MkO3N\|YoRjJ2NkKzO\|M3RC:jPh?=
MDA-MB-231	MlewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoPVNE01OCEQvF2=	MnnJOFghcA>?	NX3KdY5FTE2VTx?=	NXHFOVZocW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	M1PneFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkKzO\|M3Lz5{NE[yN\|c{PjxxYU6=
MDA-MB-468	M1rDWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLvNE02ODBizszN	M4rF[FQ5KGh?	NYTJe\|dTTE2VTx?=	M1TKcIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MkjsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MkO3N\|YoRjJ2NkKzO\|M3RC:jPh?=
T47D	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnuwNE0yODBizszN	NIr0WnU1QCCq	Mnf5SG1UVw>?	MVTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MofMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MkO3N\|YoRjJ2NkKzO\|M3RC:jPh?=
MCF7	NXrs[Yp7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXPHemF7OC1zMECwJO69VQ>?	NXK3TWF7PDhiaB?=	NE\qNZZFVVOR	NVnDRYFscW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	M361WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkKzO\|M3Lz5{NE[yN\|c{PjxxYU6=
Hs683	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWTuXYxwOC1zMECwJO69VQ>?	MXq5OkBp		MYHJR\|UxRTF{OD65JO69VQ>?	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR7NUmwO{c,OjR2OUW5NFc9N2F-
U87	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnu2NE0yODByIN88US=>	NUnVXpFXQTZiaB?=		MnqzTWM2OD1zOD60OUDPxE1?	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR7NUmwO{c,OjR2OUW5NFc9N2F-
LNZ308	NVTlVFZLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33oPVAuOTByMDFOwG0>	NVj0WZU2QTZiaB?=		NHXaTI1KSzVyPUOyOk44KM7:TR?=	M3W5d\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEm1PVA4Lz5{NES5OVkxPzxxYU6=
U87	NX[2fFJNSXCxcITvd4l{KEG\|c3H5	MnvvNVAxKM7:TR?=	M1X2e\|Q5KGh?	NVTQWoZ4TE2VTx?=	NILpRYNqdmO{ZXHz[ZMhfGinIHPhd5Bie2VvMz:3JIFkfGm4aYT5	MofjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2OEG1PFYoRjJ2NEixOVg3RC:jPh?=
U251	M2DiRmFxd3C2b4Ppd{BCe3OjeR?=	Mli4NVAxKM7:TR?=	M{TDTFQ5KGh?	NVXHPItjTE2VTx?=	MlXTbY5kemWjc3XzJJRp\SClYYPwZZNmNTNxNzDhZ5Rqfmm2eR?=	M3TmZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEixOVg3Lz5{NES4NVU5PjxxYU6=
U251	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MkSxNlQhcA>?		M{LxWWlEPTB;OE[uNlnjiIoEsfMAjVEvPThizszN	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN{Nkm1OEc,OjR\|Mk[5OVQ9N2F-
U251	NU\pOYIyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4PRelQ5KGh?		NHXZXIlKSzVyPUe1MlM16oDLwsJihKkyNjB{IN88US=>	M2WzRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{K2PVU1Lz5{NEOyOlk2PDxxYU6=
U251	MnGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4nBTlczKGh?		MoHhTWM2OD15Mj60NwKBkcLz4pEJNU41PSEQvF2=	Ml3QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|Mk[5OVQoRjJ2M{K2PVU1RC:jPh?=
U251	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnXpPVYhcA>?		Mo[0TWM2OD14OT64NwKBkcLz4pEJN{4xPCEQvF2=	M{jmOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{K2PVU1Lz5{NEOyOlk2PDxxYU6=
T98G	MkPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1fhNFAuPzVyIN88US=>	MmnUO\|IwQTZiaB?=		MYfpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	NHLrUVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEOyOFA5OCd-MkSzNlQxQDB:L3G+
U251-MG	NVL2coI{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFu5dI0xNThyMDFOwG0>	NH7Tdo84OiCq		Mlm2bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	M2jmbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEmzOlMxLz5{NEC5N\|Y{ODxxYU6=
D54-MG	MoPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXewMVgxOCEQvF2=	M37kS\|czKGh?		M3fT[IlvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB7M{[zNEc,OjRyOUO2N\|A9N2F-
SHG-44	MlPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmHrNVAuOjByIN88US=>	MnHuPVYhcA>?		NXu4dW1FUUN3ME25Mlc{KMLzIEKuNVIh\|ryP	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB4NUW2PUc,OjRyNkW1Olk9N2F-
U373	NE\TeZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYixNE0zODBizszN	MXm5OkBp		M3vi[GlEPTB;MUCuNVMhyrFiMT6wNkDPxE1?	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB4NUW2PUc,OjRyNkW1Olk9N2F-
HT-29	NUTTeldsTnWwY4Tpc44hSXO\|YYm=	NXzWO2dSPTByIN88US=>	NWf6[pV1OjRxNEigbC=>		Mn\z[Y5p[W6lZYOgeIhmKGyndnXsd{Bw\iEQsz3INmFZyqB?	NFv0NHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECzPFA3QCd-MkSwN\|gxPjh:L3G+
PC-3	MoHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEHK[ZAxNTJ3IN88US=>	NV21b3M1PDhiaB?=		MnzObY5pcWKrdIOgZ4VtdCCpcn;3eIghf2irY3igZ4FvKGKnIIDveIVvfGmjdHXkJIJ6KGy7Y3;w[Y5m	MojGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5NE[5N\|QoRjJ\|N{S2PVM1RC:jPh?=
PC-3	NHfWXlZCeG:ydH;zbZMhSXO\|YYm=	NVXBXVBTOjVizszN	NHvkV2E1QCCq		M2LwcIlv\HWlZYOgZZBweHSxc3nzJJdpcWOqIHPhckBj\SCyb4TlcpRq[XSnZDDifUBtgWOxcHXu[S=>	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd2NkmzOEc,OjN5NE[5N\|Q9N2F-
T98G	NIrYcnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHHQNYY2OC12MECg{txO	MY[xOFQhcA>?		NUHySmZ2cW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	NF;iZoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{exOVQ6QSd-MkO3NVU1QTl:L3G+
U87-MG	M{H1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEG0VFkyODBiwsXN	MoHwO\|IhcA>?		NI[5Z5BqdmirYnn0d{Bk\WyuIHfyc5d1cCC5aHnjbEBk[W5iYnWg[Y5p[W6lZXSgZpkhT1SE	NHjITYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[5Olc5QCd-MkO2PVY4QDh:L3G+
U251-MG	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXvJSGVsOTByINM1US=>	Mo\1O\|IhcA>?		NGfrRoNqdmirYnn0d{Bk\WyuIHfyc5d1cCC5aHnjbEBk[W5iYnWg[Y5p[W6lZXSgZpkhT1SE	NF7lNWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[5Olc5QCd-MkO2PVY4QDh:L3G+
LNT-229	NXXEOm1uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXmzMVExOCEQvF2=	MYSyOEBp		Mnz5bY5pcWKrdIOgZ4xwdm:pZX7pZ{B{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ4N{[zNkc,OjN4Nke2N\|I9N2F-
T98G	M3P1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVKxNE04ODBizszN	M4nTWVI1KGh?		M1vyfolvcGmkaYTzJINtd26xZ3XubYMhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	MmXEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4Nke2N\|IoRjJ\|Nk[3OlMzRC:jPh?=
U87	M4S1XWZ2dmO2aX;uJGF{e2G7	NXjlcnNPOTByINM1US=>	MlzxN{Bp		MYLlcIV3[XSnczD0bIUhdGW4ZXzzJI9nKHCFaHuxJIFv\CCyQ3jrNi=>	MmGyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4Nke0OlkoRjJ\|Nk[3OFY6RC:jPh?=
HCT116	MojWSpVv[3Srb36gRZN{[Xl?	MkDqNVAxKML3TR?=	M2TZR\|MhcA>?		M{HwS4lv\HWlZYOgeIhmKEOqa{GgVIhwe3Cqb4L5cIF1cW:w	M2jqblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|Nk[3OFY6Lz5{M{[2O\|Q3QTxxYU6=
HCT3-6	NGX3bIlHfW6ldHnvckBCe3OjeR?=	NYPURW06OTByINM1US=>	NV7NV5RIOyCq		MXHpcoR2[2W\|IITo[UBEcGtzIGDoc5NxcG:{eXzheIlwdg>?	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ4N{S2PUc,OjN4Nke0Olk9N2F-
U-87	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVuwMVQxKM7:TR?=	MVOxNkBl		MV\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NFeyS2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[0OVczQSd-MkO2OFU4Ojl:L3G+
U-87	NFzkOoRCeG:ydH;zbZMhSXO\|YYm=	NFzqZpAxNTRyIN88US=>	MkP4N{83KGR?		M3LuNIlv\HWlZYOgZZBweHSxc3nzJIlvKGKxdHig[I9{\S1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>?	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ2NUeyPUc,OjN4NEW3Nlk9N2F-
U-87	Ml\HSpVv[3Srb36gRZN{[Xl?	MXGwMVQxKM7:TR?=	MUKzM\|Yh\A>?		M33mdolv\HWlZYOgZZV1d3CqYXf5JIlvKGKxdHig[I9{\S1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>?	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ2NUeyPUc,OjN4NEW3Nlk9N2F-
GB-SCC010	NHW5fnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1fD[\|Qh\A>?		MUfJR\|UxRTJ{NjFOwG0>	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzMke1OUc,OjN4MUK3OVU9N2F-
GB-SCC026	NUHvWZpzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkXXOEBl		M17wd2lEPTB;NUOuNUDPxE1?	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzMke1OUc,OjN4MUK3OVU9N2F-
GB-SCC028	M4HEVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NID6eo01KGR?		MojXTWM2OD1zNkeg{txO	NYPjVWxORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVI4PTVpPkKzOlEzPzV3PD;hQi=>
U87	NU\I[Fg5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXroTY1xPCCm		MonKTWM2OD12NT6yJO69VQ>?	M123R\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkGyO\|U2Lz5{M{[xNlc2PTxxYU6=
U87 stem cell	MnnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYnaOXJzPCCm		NX22WYoyUUN3ME22Ok44KM7:TR?=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzMke1OUc,OjN4MUK3OVU9N2F-
TLX5 lymphoma	NWr3ZVZnS3m2b4TvfIlkcXS7IHHzd4F6				M4jxcGlEPTBiPTC1JO69VQ>?	M4XobFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493Nzd5M{mwNFgoRjd5M{mwNFg9N2F-
GM892 A	M1f1dGN6fG:2b4jpZ4l1gSCjc4PhfS=>				NEfPbHhKSzVyIE2gO{43KM7:TR?=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek84PzN7MEC4K\|44PzN7MEC4QE9iRg>?
TLX5 lymphoma	Mn3LR5l1d3SxeHnjbZR6KGG\|c3H5				NGPuc4hKSzVyIE2gOUDPxE1?	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjR3OUCxOEc,OTJ2NUmwNVQ9N2F-
HCT116	NH\hRnVEgXSxdH;4bYNqfHliYYPzZZk>		M17PZ\|Qh\GG7cx?=		NFjONIlKSzVyIE2gOE4{PCEQvF2=	NXvZ[5hnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm4NFA5ODNpPkG5PFAxQDB\|PD;hQi=>
SNB75	NWnCcWpnSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=	M2nOVFExKHWP	M1\JO\|I1KGi{cx?=		M1nqZmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU17CO\|Uh[2WubIOgZZQhOTBidV2gZYZ1\XJiMkSgbJJ{KGK7IGPSRkBie3OjeR?=	Mor2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{Nki1NlYoRjJ{Mk[4OVI3RC:jPh?=
C6	MofiRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?	NX\5UmV7OTByIIXN	NVvZcppSPDhiaILz		MY\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IILheEBEPiClZXzsd{BifCBzMECgeW0h[W[2ZYKgOFghcHK\|IHL5JI5mfXS{YXygdoVlKGmwY3;ydI9z[XSrb36gZZN{[Xl?	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ4OEWyOkc,OjJ{Nki1NlY9N2F-
SF295	MnLnRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?	NWPLRmZPOTBidV2=	MYCyOEBpenN?		M1fufGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1[yPVUh[2WubIOgZZQhOTBidV2gZYZ1\XJiMkSgbJJ{KGK7IGPSRkBie3OjeR?=	NYn2NYNmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyOlg2OjZpPkKyNlY5PTJ4PD;hQi=>
U87	NHzjV25CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NH;ESYU2KGSjeYO=		MmDXTWM2OCB;IES5JO69VQ>?	NU\BN3JpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2NFg{QDlpPkKyOlA5Ozh7PD;hQi=>
U138MG	M1jEfWN6fG:2b4jpZ4l1gSCjc4PhfS=>		MonsOFghcHK\|		NX\VOFdlUUN3MDC9JFI3KM7:TR?=	Mor2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNkm2PFIoRjJ\|ME[5OlgzRC:jPh?=
C6	NUjhfYVYS3m2b4TvfIlkcXS7IHHzd4F6		M2\LdFQ5KGi{cx?=		MmXGTWM2OCB;IEO0JO69VQ>?	MmLCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNkm2PFIoRjJ\|ME[5OlgzRC:jPh?=
A2780	M{Lrc2FvfGm2dX3vdkBie3OjeR?=		M{XCdlUh\GG7cx?=		M4LHdGlEPTBiPTC4MlUh\|ryP	M1e2UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEm1OlIxLz5{M{i5OVYzODxxYU6=
A2058	MV7BcpRqfHWvb4KgZZN{[Xl?		MkjIOUBl[Xm\|		M1fy[mlEPTBiPTCzOU42KM7:TR?=	NXvrSlJjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4PVU3OjBpPkKzPFk2PjJyPD;hQi=>
SNB19	MmPlRY51cXS3bX;yJIF{e2G7		M2PDc\|Uh\GG7cx?=		MWXJR\|UxKD1iM{eg{txO	M3f0WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEm1OlIxLz5{M{i5OVYzODxxYU6=
M8	M4O5XGFxd3C2b4Ppd{Bie3OjeR?=	MVq1NEB1dyBzMECgeW0>	M2HtVlQ5KGi{cx?=		NX;5RXVxUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDNPEBk\WyuczDhd5Nme3OnZDDhd{BieG:ydH;0bYMwdmWlcn;0bYMh[2WubIOgZZQhPTBidH:gNVAxKHWPIHHmeIVzKDR6IHjyd{BjgSCDUFOtcIFj\WynZDDhco5mgGmwIG[gZY5lKDdvQVHEJJN1[WmwaX7nMYJie2WmIH\sc5ch[3m2b33leJJq[yCjbnHsfZNqew>?	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF{NUi3O{c,OjRzMkW4O\|c9N2F-
SK-MEL-30	Ml76RZBweHSxc3nzJIF{e2G7	NGTSfIwyODBidV2=	NX[2VWx{PDhiaILz		MUTJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKFONLV3FUE0{OCClZXzsd{Bie3Onc4Pl[EBieyCjcH;weI91cWNxbnXjdo91cWNiY3XscJMh[XRiMUCwJJVOKGGodHXyJFQ5KGi{czDifUBCWENvbHHi[Yxm\CCjbn7lfIlvKFZiYX7kJFcuSUGGIIP0ZYlvcW6pLXLhd4VlKG[ub4egZ5l1d22ndILpZ{BidmGueYPpd{Bz\WyjdHn2[UB1dyClb370do9t	M4PKXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUK1PFc4Lz5{NEGyOVg4PzxxYU6=
SK-MEL-30	MkfaRZBweHSxc3nzJIF{e2G7	MYK1NEB2VQ>?	NH3XZ2k1QCCqcoO=		NV\3TIVtUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDTT{1OTUxvM{CgZ4VtdHNiYYPz[ZN{\WRiYYOgZZBweHSxdHnjM45m[3KxdHnjJINmdGy\|IHH0JFUxKHWPIHHmeIVzKDR6IHjyd{BjgSCDUFOtcIFj\WynZDDhco5mgGmwIG[gZY5lKDdvQVHEJJN1[WmwaX7nMYJie2WmIH\sc5ch[3m2b33leJJq[yCjbnHsfZNqeyC{ZXzheIl3\SC2bzDjc451em:u	NInvSFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGyOVg4Pyd-MkSxNlU5Pzd:L3G+
MNT1	MVfBdI9xfG:\|aYOgZZN{[Xl?	MWSxNFAhfU1?	MXK0PEBpenN?		NWDhPG5CUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDNUnQyKGOnbHzzJIF{e2W\|c3XkJIF{KGGyb4D0c5Rq[y:wZXPyc5Rq[yClZXzsd{BifCBzMECgeW0h[W[2ZYKgOFghcHK\|IHL5JGFRSy2uYXLlcIVlKGGwbnX4bY4hXiCjbnSgO{1CSURic4ThbY5qdmdvYnHz[YQh\myxdzDjfZRwdWW2cnnjJIFv[Wy7c3nzJJJmdGG2aY\lJJRwKGOxboTyc4w>	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF{NUi3O{c,OjRzMkW4O\|c9N2F-
MNT1	NVLXR21ISXCxcITvd4l{KGG\|c3H5	M3PqWlUxKHWP	MVK0PEBpenN?		NF\OTnRKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIF3OWFEh[2WubIOgZZN{\XO\|ZXSgZZMh[XCxcITveIlkN26nY4LveIlkKGOnbHzzJIF1KDVyIIXNJIFnfGW{IES4JIhzeyCkeTDBVGMudGGkZXzl[EBidm6neHnuJHYh[W6mIEetRWFFKHO2YXnubY5oNWKjc3XkJIZtd3diY4n0c41mfHKrYzDhcoFtgXOrczDy[YxifGm4ZTD0c{Bkd262cn;s	Mk\MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzMkW4O\|coRjJ2MUK1PFc4RC:jPh?=
A2780	MVjDfZRwfG:6aXPpeJkh[XO\|YYm=		Mm\OOUBl[Xm\|		NFu0TJhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCOjd6MDDj[YxteyCjZoTldkA2KGSjeYOgZpkhVVSWIHHzd4F6	NWXWVVhsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA1OThpPkK0PVAxPDF6PD;hQi=>
A2780/CP70	M173N2N6fG:2b4jpZ4l1gSCjc4PhfS=>		MmTIOUBl[Xm\|		MX7DfZRwfG:6aXPpeJkh[WejaX7zeEBOVVJvZHXmbYNq\W62IHj1cYFvKEF{N{iwM2NRPzBiY3XscJMh[W[2ZYKgOUBl[Xm\|IHL5JG1VXCCjc4PhfS=>	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMESxPEc,OjR7MEC0NVg9N2F-
GBM 047T	NVLhOJJDSW62aYT1cY9zKGG\|c3H5	MX[yNEB2VQ>?	MoXkNUB1dyB{IIfl[Yt{		MXPUeY1wemmlaXThcEBm\m[nY4SgbY4heGG2aXXueEBl\XKrdnXkJGdDVSByNEfUJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCwZYXyc5NxcGW{ZTDmc5Ju[XSrb36gZZQhOjBidV2gZYZ1\XJiMTD0c{AzKHenZXvzJIJ6KDOGIIT1cY9zKGOub37v[4VvcWNiYYPzZZk>	NIXuc\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO1OVU{Oid-Mk[zOVU2OzJ:L3G+
GBM 464T	MVHBcpRqfHWvb4KgZZN{[Xl?	NULpV416OjBidV2=	M3vBbFEhfG9iMjD3[YVsew>?		M3vOOnR2dW:{aXPp[IFtKGWoZnXjeEBqdiCyYYTp[Y51KGSncnn2[YQhT0KPIES2OHQh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIH7leZJwe3CqZYLlJIZwem2jdHnvckBifCB{MDD1UUBi\nSncjCxJJRwKDJid3Xlb5Mh[nliM1SgeJVud3JiY3zvco9o\W6rYzDhd5NigQ>?	NHTKdIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO1OVU{Oid-Mk[zOVU2OzJ:L3G+
U87MG	NG[0U4FHfW6ldHnvckBie3OjeR?=		M332OlMhcHK\|		M3fZZWlv\HWldHnvckBw\iCGTlGgZYxsgWyjdHnvckBqdiCqdX3hckBWQDePRzDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBPPy2PZXTHJIZwem2jdHnvckBi\nSncjCzJIhzeyCkeTDMR{1OWy:PUzDhcoFtgXOrcx?=	Ml3OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd4MUS0NVQoRjJ5NkG0OFE1RC:jPh?=
U87MG	M2XVdGFvfGm2dX3vdkBie3OjeR?=				MnGxRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iVUi3UWch[2WubIOgc5J1cG:2b4DpZ4FtdHlieHXuc4dz[W[2ZXSgbY4hUGG{bHHuJI52\GVibX;1d4Uh[nKjaX6gZZN{\XO\|ZXSgZZMhcW6mdXP0bY9vKG:oIIPsc5chfHWvb4Kg[5Jwf3SqIHH0JFUxKHWvb3yvb4ctKGm4IHHkcYlvcXO2ZYLl[EBwdmOnIHThbYx6KG[xcjC1JIRigXN?	NXW3WJM5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke2NVQ1OTRpPkK3OlE1PDF2PD;hQi=>
U87MG	NFLKV5JCdnSrdIXtc5Ih[XO\|YYm=				NHT5TVdCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDVPFdOTyClZXzsd{BwenSqb4TvdIlk[WyueTD4[Y5w\3KjZoTl[EBqdiCKYYLsZY4hdnWmZTDtc5V{\SCkcnHpckBie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDtc5V{\SC\|dYL2bZZidCCjdDC1NEB2dW:uL3vnMEBqfiCjZH3pcol{fGW{ZXSgc45k\SCmYXnsfUBnd3JiNTDkZZl{	NX3OeWZ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke2NVQ1OTRpPkK3OlE1PDF2PD;hQi=>
MDCK	MUnDfZRwfG:6aXPpeJkh[XO\|YYm=		MYGyOEBpenN?		NETtbG1EgXSxdH;4bYNqfHliYXfhbY5{fCCPRFPLJINmdGy\|IHX4dJJme3OrbnegZ4Fz[m:waXOgZY5pgWS{YYPlJFkh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHnuZ5Vj[XSnZDDmc5IhOjRiaILzJI1m[XO3cnXkJIFnfGW{IEeg[IF6eyC3bnTldkBvd3Kvb4jpZ{Bkd26maYTpc44h[nlibXX0bJlt\W6nIHLseYUhe3SjaX7pcoch[mG\|ZXSgZ4xwdm:pZX7pZ{B{fXK4aY\hcEBie3OjeR?=	NWTSbIxbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke4NlM5PzlpPkK3PFI{QDd7PD;hQi=>
MDCK	M{jOWGN6fG:2b4jpZ4l1gSCjc4PhfS=>		NWrG[5V{OjRiaILz		MoC5R5l1d3SxeHnjbZR6KGGpYXnud5QhVUSFSzDj[YxteyCneIDy[ZN{cW6pIHPhdoJwdmmlIHHubJllemG\|ZTC5JIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCrbnP1ZoF1\WRiZn;yJFI1KGi{czDt[YF{fXKnZDDh[pRmeiB5IHThfZMhfW6mZYKgbJlxd3irYzDjc45lcXSrb36gZpkhdWW2aIns[Y5mKGKudXWgd5RicW6rbnegZoF{\WRiY3zvco9o\W6rYzDzeZJ3cX[jbDDhd5NigQ>?	Mm\hQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd6MkO4O\|koRjJ5OEKzPFc6RC:jPh?=
NB-EBc1	MWTxTHRUKGG\|c3H5				MlT2dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ\|Eh[2WubIO=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
C6	MYjDfZRwfG:6aXPpeJkh[XO\|YYm=		MmXZOEBl[Xm\|		MXjFR\|UxKD1iMU[uOUDPxE1?	MkHrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFExNyd-Q3jFUWJNRC:jPh?=
U87	NXTIS2h7S3m2b4TvfIlkcXS7IHHzd4F6		NHPz[lg4OiCqcoO=		M17iUGlEPTBiPTCxPU4{QCEQvF2=	NE[3fWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5OTBxJ{7DbGVOSkx:L3G+
SNB19	Mlz4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MnL5O{Bl[Xm\|		MnXWS2k2OCB;IEO1Mlch\|ryP	MlHCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFExNyd-Q3jFUWJNRC:jPh?=
SNB19	NUHQcpBET3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M2jt[\|ch\GG7cx?=		MnXOS2k2OCB;IES1MlYh\|ryP	NYn1PIJmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDFyLze+R4hGVUKOPD;hQi=>
U373	NWjtNmpqTnWwY4Tpc44h[XO\|YYm=	NFv5[XgyODBidV2=	NHTW[Ys4OiCqcoO=		NVPlZ41FUW6mdXP0bY9vKG:oIHTveYJt\SC\|dILhcoRm\CCGTlGgZpJm[WtiaX6g[Y1xfHlidnXjeI9zKHS{YX7z[oVkfGWmIHj1cYFvKFV\|N{OgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4h\2GvbXGtTFJCYCCuZY\lcEBifCBzMECgeW0h[W[2ZYKgO\|IhcHK\|IHL5JIZtd3diY4n0c41mfHK7	MmP3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFExNyd-Q3jFUWJNRC:jPh?=
Glioma	MYTBcpRqfHWvb4KgZZN{[Xl?				M4G4NGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JGhwdW9ic3HwbYVveyBqaIXtZY4qKEeuaX;tZUBk\WyuczD4[Y5w\3KjZoTl[EBqdiC2cnHud4dmdmmlIH3veZNmKGG\|c3Xzd4VlKGG\|IH3veZNmKHO3co\peoFt	M4PtVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFgyOC9pPlPoSW1DVDxxYU6=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pERK / ERK / p-p38 / p38; PubMed: 24436439 Stem Cells Transl Med Cells were treated with TMZ (0.5 mM) time dependently, and Western blotting was used to analyze for phosphorylated ERK and p38 MAPK expression. DR5 / c-FLIP / Survivin / XIAP; PubMed: 24436439 Stem Cells Transl Med Western blot analysis showing expressions in DR5 and antiapoptotic proteins (c-FLIP, survivin, and XIAP) in glioma cells treated with increasing doses of TMZ (0–2 mM) for 24 hours.	24436439
Growth inhibition assay	Cell viability; PubMed: 25751281 Mol Pharm Distinct temozolomide-resistance for MGMT-expressing (SF767) and MGMT-negative (U87) GBM cells was assessed.	25751281
Immunofluorescence	Phalloidin / Phospho-H2A.X; PubMed: 27375225 Sci Rep Immunofluorescence analysis of the level of phospho-H2A.X in nucleus which can reflect DNA damage response increased significantly at day 6, peaked during days 7-10 and decreased significantly at day 12 after treatment temozolomide (200 μM). cleaved caspase-3; PubMed: 25663820 Cancer Cell Int Representative Photomicrographs of cleaved caspase-3 immunoreactivity in control (DMSO treated) and treated group of U87 cells. Base line immunofluorescence was detected in control group. Significant Increase in immunofluorescence is detected in all treated groups with the highest observed intensity in combination treatment group (NA-2 + TMZ).	27375225 25663820

In vivo

After a daily i.p. dose of 40 mg/kg for 5 consecutive days (days 1-5 after tumor transplant), methazolastone increases life-span by 86% in L-1210 and 22% in L-1210/BCNU. In L-1210/BCNU no effect is seen after 100 μM or 200 μM treatment; only 400 μM methazolastone produced an accumulation of cells in premitotic phase but much less than in L-1210. In L-1210/BCNU the maximum accumulation of cells in SL-G2-M is, after 48 hours-72 hours, approximately 30% as compared to 23% in untreated cells. Cells accumulates in SL-G2-M occurred too when L- 1210 leukemia-bearing mice are treated i.v. with methazola stone (40 mg/kg). No such effect is seen on L-1210/BCNU cells from mice given the same drug dose. ^[1]

Protocol

Cell Research:

^[1]

- Collapse

Cell lines: L-1210 and L-1210/BCNU cells
Concentrations: 0 μM -100 μM
Incubation Time: l hours
Method:
L-1210 and L-1210/BCNU cells are seeded at 0.2 × 10₄ cells/mL and incubated for 24 hours. The cultures are treated with Methazolastone for l hours at 37oC, then washed twice in PBS by centrifugation and resuspended in fresh medium. Controls and treated samples are diluted in fresh medium 1:4 at 48 hours and 1:2 at 96 hours. Using these dilutions cell concentrations throughout the experiments are between 3 × 10₅ and 8 × 10₅/mL. Control growth is logarithmic in this range.

(Only for Reference)

Animal Research:

^[1]

- Collapse

Animal Models: DBA/2 mice with L-1210 and L-1210/BCNU cells
Dosages: 40 mg/kg
Administration: Administered via i.v.
(Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	38 mg/mL (195.72 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Temozolomide SDF

Molecular Weight	194.15
Formula	C₆H₆N₆O₂
CAS No.	85622-93-1
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	CCRG81045, NSC 362856,TMZ
Smiles	CN1C(=O)N2C=NC(=C2N=N1)C(=O)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04610736	Not yet recruiting	Drug: Temozolomide Oral Suspension	Pediatric Cancer	Orphelia Pharma\|ClinSearch	January 2021	Phase 1
NCT04514393	Not yet recruiting	Drug: Methotrexate\|Drug: Ibrutinib\|Drug: Temozolomide	Primary Central Nervous System Lymphoma\|PCNSL\|Non Hodgkin Lymphoma	Huiqiang Huang\|Guangdong 999 Brain Hospital\|Nanfang Hospital of Southern Medical University\|Xian-Janssen Pharmaceutical Ltd.\|Sun Yat-sen University	December 1 2020	Phase 2
NCT04238819	Recruiting	Drug: Abemaciclib\|Drug: Irinotecan\|Drug: Temozolomide	Relapsed Solid Tumor\|Refractory Solid Tumor	Eli Lilly and Company	November 9 2020	Phase 1
NCT03796507	Not yet recruiting	Drug: Temozolomide	Glioma of Brain	University of Rochester\|National Institutes of Health (NIH)	September 1 2020	Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

SCR7 ^New

SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ). It increases the efficiency of HDR-mediated genome editing up to 19-fold using CRISPR/Cas9 in mammalian cells and mouse embryos.
Blasticidin S HCl ^New

Blasticidin S HCl is a nucleoside antibiotic isolated from Stretomyces girseochromogenes, and acts as a DNA and protein synthesis inhibitor, used to select transfected cells carrying bsr or BSD resistance genes.
YK-4-279 ^New

YK-4-279 is a potent inhibitor of EWS-FLI1 binding to RNA helicase A (RHA).
Cisplatin

Cisplatin (cisplatinum, cis-diamminedichloroplatinum II, CDDP) is an inorganic platinum complex, which is able to inhibit DNA synthesis by conforming DNA adducts in tumor cells. Cisplatin activates ferroptosis and induces autophagy. Solutions are best fresh-prepared.

Features:One of the most widely used and most potent chemotherapeutic agents.
Gemcitabine HCl

Gemcitabine HCl (LY188011) is a DNA synthesis inhibitor with IC50 of 50 nM, 40 nM, 18 nM and 12 nM in PANC1, MIAPaCa2, BxPC3 and Capan2 cells, respectively.

Features:Gemcitabine has been used to treat pancreatic cancer and has demonstrated effective anti-tumor activity.
Oxaliplatin

Oxaliplatin (L-OHP) is a DNA alkylating agent that activates autophagy. Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells. DMF is recommended for dissolution. Solutions are best fresh-prepared.
Bleomycin Sulfate

Bleomycin Sulfate (NSC125066) is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.
Gemcitabine

Gemcitabine (LY-188011, NSC 613327), a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy. Gemcitabine induces a potent p53-dependent apoptosis.
Fluorouracil (5-Fluorouracil, 5-FU)

Fluorouracil (5-Fluorouracil, 5-FU, NSC 19893) is a DNA/RNA synthesis inhibitor, which interrupts nucleotide synthetic by inhibiting thymidylate synthase (TS) in tumor cells. Fluorouracil induces apoptosis and can be used in the treatment of HIV.
Carboplatin

Carboplatin (JM-8, CBDCA, NSC 241240) is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells. Solutions are best fresh-prepared.

Features:A DNA synthesis inhibitor.

Choose Your Country or Region

By Signaling Pathways

By product type

Temozolomide